14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today FOLD ranks #14063 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Amicus Therapeutics Stock Forecast NASDAQ:FOLD

$9.19 (-3.26%)

Volume: 2M

Closed: Jan 26, 2022

Hollow Logo Score: -3.341

Amicus Therapeutics Stock Forecast

$9.19 (-3.26%)

Volume: 2M

Closed: Jan 26, 2022

Score Hollow Logo -3.341

Amicus Therapeutics Company Profile

1 Cedar Brook Drive

Cranbury NJ 08512



Industry: Biotechnology

Sector: Healthcare

Amicus Therapeutics


Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, a small molecule, which has completed Phase III studies that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; ATB200 that is in Phase II studies to treat pompe disease; AT2221, which is in Phase II studies for the treatment of pompe disease; and AT3375 to treat Parkinson's disease. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE